AstraZeneca’s respiratory group scores FDA OK for a blockbuster severe asthma drug
This was the year that analysts had fixed on AstraZeneca’s first hurdle in a combination study for lung cancer as the big catalyst of the year, which would show whether or not CEO Pascal Soriot was on track to finally turn the pharma giant around after five long years at the helm.
AstraZeneca missed that goal, causing considerable fretting about its future. But it didn’t end there. Events have conspired to provide AstraZeneca with a series of H2 wins, capped today with an FDA approval for its asthma drug benralizumab.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.